Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects.

Le, Hannah; Ryan, Kellie; Wahlstrom, Svea K; Maculaitis, Martine C; Will, Oliver; Mulvihill, Emily; LeBlanc, Thomas W

Le, Hannah; Ryan, Kellie; Wahlstrom, Svea K; Maculaitis, Martine C; Will, Oliver; Mulvihill, Emily; LeBlanc, Thomas W.

Afiliação

Le H; US Medical Affairs, AstraZeneca, Gaithersburg, MD, USA.
Ryan K; US Medical Affairs, AstraZeneca, Gaithersburg, MD, USA.
Wahlstrom SK; US Patient Safety, AstraZeneca, Wilmington, DE, USA.
Maculaitis MC; Kantar, Health Division, New York, NY, USA.
Will O; Kantar, Health Division, Horsham, PA, USA.
Mulvihill E; Kantar, Health Division, St. Louis, MO, USA.
LeBlanc TW; Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, USA.

Patient Prefer Adherence ; 15: 99-110, 2021.

Article em En | MEDLINE | ID: mdl-33519195

Palavras-chave

B-cell; chronic; leukemia; lymphocytic; oncologists; progression-free survival; tumor lysis syndrome

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Patient Prefer Adherence Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google